MedPath

Assessment Effect of Bopronorphin Neonates With Obstinence Syndrom

Phase 3
Recruiting
Conditions
eonatal Abstinence Syndrome.
Neonatal withdrawal symptoms from maternal use of drugs of addiction
Registration Number
IRCT20181231042183N1
Lead Sponsor
Birjand University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Postnatal Age<7 Days
Gestational Age= 35 Weeks
Prenatal Opium Exposure
Symptomatic Patient And 3 Fingan Score =8 In 3 Hours Or 2 Fingan Score=12
No Siezure History
No Major Congenital Anomaly
No Unstablity In Blood Pressure And Hemodynamic
No Major Medical Unstability In Association Of Withdrawal Syndrome

Exclusion Criteria

Analgesic Consumption and withdrawal syndrome

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Admit Duration. Timepoint: Duration of Admit. Method of measurement: Observation of physician.;Drugs Complications. Timepoint: Admit Duration. Method of measurement: Observation of physician.;Apnea. Timepoint: Admit Duration. Method of measurement: Observation of physician.;Feeding. Timepoint: Admit Duration. Method of measurement: Observation of physician.;Blood Pressure. Timepoint: Admit Duration. Method of measurement: Mercurial Pressure-Gauge Device.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath